Cost-effectiveness analysis of second-generation androgen receptor antagonists for the treatment of metastatic hormone-sensitive prostate cancer
For Chinese mHSPC patients, darolutamide is the most cost-effective treatment at a WTP threshold of ¥287,391/QALY, followed by apalutamide, with enzalutamide being less favorable.
Authors
- Ling Huang (ORCID: https://orcid.org/0000-0001-5584-0419)
- Yang Yang (ORCID: https://orcid.org/0000-0002-8190-1825)
- Yong Chen (ORCID: https://orcid.org/0009-0006-9094-7012)
- Yaqing Chen (ORCID: https://orcid.org/0009-0007-6308-5637)
Institutions
- First Affiliated Hospital of Guangdong Pharmaceutical University (CN)
Publication Details
- Journal
- Frontiers in Public Health
- Published
- 2025-10-16
- DOI
- https://doi.org/10.3389/fpubh.2025.1680002
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00